Citi initiated coverage of Rhythm Pharmaceuticals (RYTM) with a Buy rating and $136 price target The firm says Rhythm is a commercial-stage biotech developing therapies that target the MC4R pathway for rare neuroendocrine diseases. Citi sees a high probability of approval for Imcivree in acquired hypothalamic obesity into the FDA action date of March 20, 2026.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm announces presentation of four datasets at ObesityWeek
- Rhythm Pharmaceuticals price target raised to $114 from $105 at Canaccord
- Positive Outlook for Rhythm Pharmaceuticals Despite FDA Review Delay and Financial Shortfall
- Rhythm Pharmaceuticals Faces FDA Review Extension
- Rhythm announces FDA extension of review period for IMCIVREE